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High-level secretion of native 
recombinant human calreticulin in yeast
Evaldas Čiplys1, Eimantas Žitkus1, Leslie I. Gold2, Julien Daubriac2, Savvas C. Pavlides2, Peter Højrup3, 
Gunnar Houen4, Wen‑An Wang5, Marek Michalak5 and Rimantas Slibinskas1*
Abstract 
Background: Calreticulin (CRT) resides in the endoplasmic reticulum (ER) and functions to chaperone proteins, 
ensuring proper folding, and intracellular Ca2+ homeostasis. Emerging evidence shows that CRT is a multifunctional 
protein with significant roles in physiological and pathological processes with presence both inside and outside of 
the ER, including the cell surface and extracellular space. These recent findings suggest the possible use of this ER 
chaperone in development of new therapeutic pharmaceuticals. Our study was focused on human CRT production in 
two yeast species, Saccharomyces cerevisiae and Pichia pastoris.
Results: Expression of a full‑length human CRT precursor including its native signal sequence resulted in high‑level 
secretion of mature recombinant protein into the culture medium by both S. cerevisiae and P. pastoris. To ensure the 
structural and functional quality of the yeast‑derived CRTs, we compared yeast‑secreted human recombinant CRT 
with native CRT isolated from human placenta. In ESI–MS (electrospray ionization mass spectrometry), both native 
and recombinant full‑length CRT showed an identical molecular weight (mass) of 46,466 Da and were monomeric 
by non‑denaturing PAGE. Moreover, limited trypsin digestion yielded identical fragment patterns of calcium‑binding 
recombinant and native CRT suggesting that the yeast‑derived CRT was correctly folded. Furthermore, both native 
and recombinant CRT induced cellular proliferation (MTS assay) and migration of human dermal fibroblasts (in vitro 
wound healing assay) with the same specific activities (peak responses at 1–10 ng/ml) indicating that the functional 
integrity of yeast‑derived CRT was completely preserved. Simple one‑step purification of CRT from shake‑flask cul‑
tures resulted in highly pure recombinant CRT protein with yields reaching 75 % of total secreted protein and with 
production levels of 60 and 200 mg/l from S. cerevisiae and P. pastoris, respectively. Finally, cultivation of P. pastoris in a 
bioreactor yielded CRT secretion titer to exceed 1.5 g/l of culture medium.
Conclusions: Yeasts are able to correctly process and secrete large amounts of mature recombinant human CRT 
equally and fully biologically active as native human CRT. This allows efficient production of high‑quality CRT protein 
in grams per liter scale.
© 2015 Čiplys et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
CRT functions in the ER as a calcium-binding chaper-
one involved in a variety of biological processes includ-
ing quality control of protein folding [1–3], regulation of 
calcium homeostasis [2, 4, 5] and MHC class I antigen 
processing [6, 7]. In addition to these essential intracel-
lular functions, CRT has other important functional 
roles outside of the ER that are critical to various physi-
ological and disease processes, particularly stress-related 
disease [8]. For example, CRT has a significant role in 
both the innate and adaptive immune response and cell 
surface CRT is required for phagocytosis of apoptotic 
cells [9]. In this vein, both intracellular and extracellular 
CRT are important in the host immune response to can-
cer with respect to activation of T cells, peptide loading 
with tumor antigens, and in the phagocytosis of tumor 
cells expressing cell surface CRT, by dendritic cells. CRT 
is also important to the success of certain chemothera-
pies [10–12]. In addition, CRT is integrally important in 
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the process of healing cutaneous wounds [13, 14]. These 
functions are directed by the surface-exposed or secreted 
protein form of CRT [14, 15]. The translocation of CRT 
to the cell surface can be induced by ER stress in some 
cell types, which is triggered by various stimuli includ-
ing anthracyclines, irradiation and reduction of ER 
Ca2+ levels [16–18]. Importantly, since exogenous CRT 
rescues CRT-deficient cells in numerous and different 
CRT-dependent functions, such as adhesion, migration, 
phagocytosis, and immunoregulation [8], exogenously 
supplied CRT has significant therapeutic potential for a 
variety of indications including impaired diabetic wound 
healing and cancer therapy [8, 10, 11, 13, 14, 19]. In fact, 
chronic wound healing and particularly impaired cutane-
ous healing as a consequence of diabetes is a global seri-
ous unmet medical need and economic challenge (26 
million worldwide patients). Taken together, future fun-
damental, applied and therapeutic studies and use will 
likely require large amounts of affordable high-quality 
recombinant human CRT protein with native functional 
capacity, insofar as possible.
Here we show that expression of a full-length human 
CRT precursor in yeast cells can be employed to obtain 
a high level of secretion of mature native recombinant 
CRT protein. Fed-batch fermentation of P. pastoris cul-
ture resulted in more than 1.5  g/l CRT secretion yield. 
Comparison of yeast-secreted recombinant CRT to 
native CRT isolated from human placenta showed that 
the recombinant protein has apparent similar molecular 
and functional properties as the native protein. From this 
study, we can conclude that yeast is an excellent host for 
industrially relevant production of native recombinant 
CRT protein.
Results and discussion
Expression and purification of human CRT from yeasts  
S. cerevisiae and P. pastoris from culture medium
Our results herein show that expression of a full-length 
human CRT precursor including its native signal 
sequence resulted in a high-level secretion of the recom-
binant protein into the culture medium by two yeast 
species, S. cerevisiae and P. pastoris. It should be noted 
that the expressed human CRT polypeptide precursor 
contained exactly the same native amino acid sequence 
as CRT precursor in human cells. Neither yeast secretion 
signal sequences, nor any tags for purification were used 
in this study. In the S. cerevisiae system, we expressed 
the gene encoding CRT under control of the yeast PGK1 
gene promoter in the same vector, pFDC [20], that was 
previously used for the expression of secreted human 
BiP and ERp57 in yeast [21, 22] and show that CRT 
was similarly secreted into the culture medium (Fig.  1). 
However, quantities of the secreted CRT protein were 
much higher than previously observed for human BiP or 
ERp57. According to data obtained from densitometric 
analysis of SDS–PAGE gels, secreted human recombi-
nant CRT constituted approximately 60–65 % of the total 
S. cerevisiae secreted proteins. The CRT secretion titer 
was approximately 60-65  mg from 1 L of yeast culture 
medium. The amount of secreted CRT in S.  cerevisiae 
culture supernatant was about four- to fivefold higher 
than either human BiP or ERp57 under the same condi-
tions (for direct comparison of secretion levels see SDS-
PAGE gel in Additional file  1). CRT secretion was also 
achieved by using methanol-inducible yeast AOX1 gene 
Fig. 1 SDS‑PAGE analysis of yeast culture media and purified 
recombinant human CRT samples. Upper panel yeast culture media 
after CRT expression in P. pastoris and S. cerevisiae (10× concentrated 
media supernatants). A media from yeast strains expressing human 
CRT. B media from control yeast cells without CRT gene. Lower panel 
purified secreted recombinant human CRT protein (C lanes). M 
unstained protein ladder (ThermoScientific, cat. no. 26614)
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promoter in P. pastoris (Fig. 1). Shake flask cultures of the 
selected P. pastoris transformant, CPp9, with multicopy 
integrations of CRT expression cassettes yielded approxi-
mately 180–200 mg/l of secreted CRT and the purity of 
the full-length mature human CRT recombinant protein 
in crude P. pastoris culture medium was approximately 
70–75 %. There were also a few minor bands of partially 
degraded CRT protein detected in the culture media 
from both yeasts by SDS-PAGE and Western blot, but 
these bands were not included in calculations.
The high-level secretion of recombinant human CRT 
in yeast culture media allowed one-step purification by 
Q-Sepharose ion-exchange chromatography. CRT is 
an acidic protein with a pI of 4.29 and contains an Asp/
Glu/Lys-rich C-domain. Such biophysical characteris-
tics allow strong binding to an anion-exchange column 
even at low pH and increased ionic strength. This puri-
fication step efficiently removed yeast proteins and other 
impurities. However, lower molecular weight (MW) 
forms of CRT were co-purified with the main form of the 
full-length CRT protein in the same single elution peak 
(Additional file 2). There was also a slightly higher MW 
protein form detected by SDS-PAGE in elution frac-
tions of purified CRT from both yeasts, which was more 
prominent in P. pastoris-derived preparation (Additional 
file 2b, d). The elution profile showed that the CRT peak 
was not symmetrical and even had a smaller shoulder 
in preparation from P. pastoris (Additional file 2c), pos-
sibly due to presence of additional minor protein forms 
observed. Western blotting analysis showed that minor 
bands visible by SDS-PAGE of purified protein also rep-
resent CRT as they reacted with monoclonal anti-CRT 
antibody (Additional file 3). It was also evident that CRT 
fragments of lower MW were generated during biosyn-
thesis, because they were also observed in yeast culture 
medium (Fig. 1; Additional file 3). Moreover, we did not 
observe such multiple fragments of lower MW by native 
PAGE (Fig.  2). It seems that after proteolytic cleavage 
lower MW fragments are still maintained within CRT 
molecules by intra-molecular interactions, while they 
are separated only under denaturing conditions. Prob-
ably, such protein form should be considered as “nicked”, 
rather than “partially degraded”. SDS-PAGE and immu-
noblotting showed the same overall pattern of “nicked” or 
partially degraded forms between different preparations 
(Additional file  4). According to densitometric analysis 
of Coomassie-stained SDS–PAGE gels, the major intact 
CRT protein form constituted for approximately 80  % 
in P. pastoris- and 85 % in S. cerevisiae-derived prepara-
tions. The overall purity of CRT including minor protein 
forms was considerably higher than 90 % in preparations 
from both yeasts. Furthermore, recombinant CRT puri-
fied from P. pastoris, analysed for protein impurities by 
quantitative evaluation of tryptic peptides using a HDMS 
Synapt G2 mass spectrometer, showed 98–99  % purity. 
Therefore, this simple one-step purification generated 
highly pure recombinant secreted human CRT contain-
ing minor amounts of nicked or partially degraded pro-
tein forms. The yields of purified CRT were 45–50 and 
130–150 mg/l in S. cerevisiae and P. pastoris, respectively.
Recombinant human CRT secreted by yeast and CRT 
protein isolated from human placenta have similar 
molecular features
The pattern from tryptic peptide mass fingerprinting of 
purified secreted CRT from both yeast species was con-
firmed to be the same as mature CRT sequence from 
human cells (without the signal sequence) including a tryp-
tic peptide (EPAVYFK) corresponding to the N-terminal 
sequence of native mature CRT [23–25] (Fig. 3). Moreover, 
using a comprehensive technique with a HDMS Synapt G2 
system, peptide mass fingerprinting of P. pastoris-secreted 
CRT was able to provide >90 % amino acid sequence cov-
erage (Fig.  3). Although we were not able to identify the 
N-terminal tryptic peptide by this method, a C-terminal 
human CRT peptide including the intact ER retention/
retrieval signal KDEL was identified (underlined in Fig. 3).
Fig. 2 Native PAGE of human placental and recombinant CRTs. Blue 
native PAGE is shown above and native PAGE below. 5 μg of purified 
CRT was loaded onto each gel lane. Protein source is indicated at the 
lanes as follows: Hn native CRT from human placenta; Sc recombinant 
secreted human CRT from S. cerevisiae; Pp recombinant secreted 
human CRT from P. pastoris. BSA was loaded as molecular weight 
marker
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To ensure the structural and functional integrity of the 
yeast-derived CRTs, we compared yeast-secreted human 
recombinant CRT with native CRT isolated from human 
placenta [26]. ESI–MS of a whole intact native and 
recombinant CRTs showed basically the same molecu-
lar weight (MW) of approximately 46,466  Da, which 
exactly corresponds to the theoretically calculated MW 
of mature human CRT (Fig.  4). Moreover, N-terminal 
sequencing by Edman degradation confirmed that the 
first five N-terminal amino acid sequences of P. pas-
toris- and S. cerevisiae-expressed proteins were NH2-
EPAVY and corresponded to the N-terminal amino 
acid sequence of mature human CRT. Taken together, 
these results indicated that native CRT human ER signal 
sequence was recognized and correctly processed (i.e., 
cleaved from the precursor to form the mature protein) 
in yeast cells, and this supported translocation of recom-
binant protein into the ER lumen followed by secretion 
into the culture media. Furthermore, according to the 
determined MW, both native and recombinant CRTs 
are pure polypeptide chains without additional groups 
attached due to post-translational modification. The lack 
of such post-translational modifications as glycosylation 
and phosphorylation, was shown in previous analysis of 
human placental CRT [26]. Nevertheless, it should be 
noted that our study was focused on comparison of CRTs 
from different sources, rather than on analysis of possi-
ble post-translational modifications. The protein should 
contain a disulfide bond [26] and there were reports 
on various CRT modifications including acetylation of 
Fig. 3 Tryptic peptide mass fingerprinting of yeast‑secreted CRT protein. Purified secreted CRT protein was analyzed by trypsin digestion and 
MALDI‑TOF/TOF tandem MS/MS (upper panels) or nano‑LC coupled with HDMS Synapt G2 mass spectrometer (lower panels). Human CRT was 
identified with ~66 % or ~91 % sequence coverage in S. cerevisiae‑ or P. pastoris‑derived samples, respectively (identified sequences are indicated in 
bold). The N‑terminal tryptic peptide (begins not from lysine or arginine), and C‑terminal tryptic peptide (contains C‑terminal ‑KDEL sequence), are 
underlined
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lysine residues [27, 28], glycosylation [29] and citrul-
lination [30] in different tissues or under specific con-
ditions. Some modification of both recombinant and 
native placental CRTs might be suspected from a minor 
form of slightly higher MW observed in SDS-PAGE, 
as it was mentioned above. According to densitomet-
ric scanning of SDS-PAGE gels it constituted up to 2 % 
of protein purified from P. pastoris or human placenta, 
and even less amount of protein from S. cerevisiae. This 
minor band should represent the same CRT protein as 
it reacted with anti-CRT antibodies (Additional files 1, 
3 for S. cerevisiae and P. pastoris, respectively). However, 
both minor and major bands have been characterised by 
MS and no differences were seen. The most likely expla-
nation may be that the slower migrating band represents 
a separate conformation, which is stable during the time 
of electrophoresis, possibly proline cis–trans isomerism 
(CRT has many prolines). At least, they certainly do not 
represent acetylation or glycosylation. Although we did 
not perform extensive tests for modifications and can 
thus not exclude that some modifications may still exist, 
the methods used in this study did not detect any differ-
ence in modification status between native and recombi-
nant CRTs. Taken together, based on the analyses herein, 
the native and recombinant CRT proteins appear to show 
similar molecular characteristics.
Oligomerization and conformation of yeast‑secreted 
and placental CRTs
Oligomerization analysis by native and blue native PAGE 
showed that both placental and recombinant CRTs were 
present only in monomeric form (Fig.  2). However, we 
observed a slight difference in mobility of CRTs purified 
from human placenta and yeast culture media. Native 
human protein migrated slightly faster than recombinant 
CRTs, and this suggested a conformational difference. In 
order to check possible influence of different buffers used 
for storage of recombinant and placental CRTs, we have 
transferred the latter to storage buffer of recombinant 
CRTs and repeated both native PAGEs. Indeed, buffer 
change resulted in slower migration of placental CRT and 
it became very similar to that of yeast-secreted proteins 
(Additional file 5).
Conformation of native and recombinant CRTs was 
analysed by limited proteolysis with trypsin. It has been 
reported that the binding of Ca2+ to CRT protects a 
20–30 kDa CRT domain against trypsin digestion due to 
a Ca2+-dependent conformational change in the protein 
[31]. In agreement with this report, by SDS-PAGE analy-
sis, the same  ~23  kDa CRT fragment and digestion pat-
tern was obtained for the native and recombinant CRTs in 
the presence of Ca2+ ions (Fig. 5 middle panel), whereas 
addition of EGTA to chelate Ca2+ resulted in rapid pro-
tein degradation and the absence of a protected fragment 
(Fig.  5 right panel). We also noticed that CRT proteins 
showed an additional minor trypsin-resistant fragment 
of  ~50  kDa (Fig.  5 middle panel). A similar  ~50  kDa 
trypsin-resistant fragment for the placental CRT was 
reported in a previous study [26]. Taken together, native 
placental and recombinant human CRTs showed similar 
sensitivity to trypsin digestion indicating a correct fold-
ing that has also been previously reported for rabbit CRT 
expressed in P.  pastoris [32]. The C-terminal part of the 
rabbit protein was removed fairly rapidly to give an appar-
ent MW 50-kDa fragment, which was further degraded, 
leaving a protease-resistant fragment of an apparent 
27  kDa [31]. Therefore, limited proteolysis with trypsin 
indicated that yeast-expressed human CRT was a cor-
rectly folded Ca2+ binding protein that harbored similar 
properties to both native human placental CRT [26] and 
recombinant rabbit CRT expressed in P. pastoris [31, 32].
Fig. 4 Deconvoluted ESI–MS spectra of native and recombinant 
human CRTs. Analyzed proteins were purified from human placenta 
(native CRT) or from culture media of yeast P. pastoris and S. cerevisiae, 
respectively. Results of N‑terminal Edman sequencing are shown as 
inserts for secreted recombinant CRTs
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Functional analysis of the recombinant and native human 
CRTs
It was previously shown that topically applied CRT 
markedly enhanced the rate and quality of wound heal-
ing in porcine and diabetic mouse models [8, 13, 14, 33]. 
In these studies, CRT was shown to dose-dependently 
induce wound healing functions of migration, prolif-
eration, and matrix protein induction in human der-
mal fibroblasts as previously shown in identical in  vitro 
assays [13, 14]. To ensure that CRT secreted from yeast 
was biologically active, we directly compared effects of 
native and recombinant CRTs in  vitro, for their ability 
to induce human fibroblast proliferation, using an MTS 
cell proliferation assay, (Fig.  6) and migration, using a 
classic in vitro wound healing scratch plate assay (Fig. 7). 
As shown in Fig.  6, human placental and yeast-derived 
CRT from both, P. pastoris and S. cerevisiae, stimulated 
proliferation at the same peak of activity of 10  ng/ml. 
At this concentration, native CRT stimulated prolifera-
tion by 1.25-fold (p < 0.01) and CRT from P. pastoris and 
S. cerevisiae showed a 1.37 (p ≤  0.0001) and 1.344-fold 
(p  ≤  0.001) increase, respectively; (untreated control 
of 0.5 % serum is set at 1.0; n = 6). By comparison, the 
10  % FBS positive control stimulated proliferation 1.6-
fold over untreated control (p ≤  0.0001). There was no 
statistically significant difference among all of the CRTs 
with all treatment doses. Therefore, we conclude that all 
CRTs were functionally indistinguishable (Fig. 6). As we 
have previously shown with receptor mediated responses 
such as cell proliferation and migration, a peak of activ-
ity is obtained, which wanes at higher concentrations of 
the protein [13, 14]. This can be explained by receptor 
saturation at concentrations higher than the peak activity 
shown. In Fig. 6, this downward trend at 100 ng/ml CRT 
was not statistically significantly different than CRT at 
10 ng/ml.
Using the scratch plate method as an in  vitro wound 
healing assay, after 24  h of treatment, 75–95  % wound 
closure was achieved with all CRT proteins with a peak 
concentration of 1.0  ng/ml compared to the 0.5  % FBS 
untreated control, which showed 53  % closure at 24  h 
(Fig. 7a). Specifically, at this peak concentration, a statis-
tically significant induction of wound closure by native 
CRT of 81.3 % (p ≤ 0.05) and CRT produced by P. pas-
toris of 94.6  % (p  ≤  0.001) over the untreated control 
was obtained (n  =  1). Whereas statistical significance 
in induction of wound closure at this concentration was 
not reached by CRT from S. cerevisiae, there was no dif-
ference among the three CRTs at 1.0  ng/ml. To test the 
sensitivity of CRT responsiveness in stimulating migra-
tion as measures by wound closure on the scratch, the 
plates were analyzed at 6 h post-treatment. As shown in 
Fig.  7b, there was a statistically significant induction of 
wound closure for native and S. cerevisiae-derived CRTs 
at both 1.0 and 10  ng/ml (n =  2). At the peak concen-
tration of 10 ng/ml CRT, native and S. cerevisiae-secreted 
CRTs stimulated wound closure at 9.3 % (p ≤ 0.01) and 
8.7 % (p ≤ 0.05), respectively over the untreated control 
of 5.5 % closure. There weren’t any statistically significant 
differences among all CRTs at any dose. Notably, the peak 
of activity in induction of wound closure was similar with 
Fig. 5 Partial digestion of native and recombinant human CRTs with 
trypsin. M unstained protein ladder (ThermoScientific, cat. no. 26614). 
Undigested CRTs are loaded to the left, CRTs digested with trypsin in 
the presence of 3 mM CaCl2—in the middle, whereas CRTs digested 
with trypsin after addition of EGTA to chelate calcium ions—in the 
right gel lanes. Source of protein is indicated as described in Fig. 2 
legend
Fig. 6 Cellular proliferation induced by native and yeast‑derived 
CRTs. Native CRT isolated from human placenta, and recombinant 
human CRT purified from yeast P. pastoris and S. cerevisiae were incu‑
bated with human fibroblasts and the assay performed as described 
in “Methods”. Cellular proliferation was compared to the untreated 
control of cells incubated in 0.5 % FBS medium without CRT. Experi‑
ments were performed in triplicate (n = 6) and error bars represent 
standard error of the mean (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and 
****p ≤ 0.0001; Dunnett’s test for statistical significance)
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native CRT compared to the two yeast-derived recom-
binant CRTs suggesting that the functional integrity 
of yeast-derived CRT was preserved. As described 
above, the downward trend in activity at 100 ng/ml was 
obtained previously [13, 14] and likely represents recep-
tor saturation at higher concentrations. Whereas recep-
tor signaling via the LRP1 has been shown for migration 
[34], which might be operating in the scratch plate assay, 
the receptor that mediates proliferation is unknown. 
Earlier we reported that ATPase activity of yeast-
secreted human GRP78/BiP protein exceeded the activ-
ity of E. coli-derived recombinant human BiP threefold 
[21], whereas yeast-secreted human ERp57 catalyzed 
the reduction of insulin at a faster rate than analogous 
recombinant human protein expressed in E. coli [22]. 
However, comparative biological activities to native 
human proteins were precluded since native protein 
was not available. The use of native CRT protein isolated 
from human placenta herein afforded the opportunity to 
optimally compare the yeast-secreted recombinant pro-
tein with purified native human CRT. Similar functional 
activity of native CRT and recombinant CRT strongly 
suggest that the synthesized and secreted recombinant 
CRT should have the same effect on wound healing 
in vivo, as cellular migration and proliferation are critical 
functions that enable the wound repair process [13]. As 
animal studies showed that topical CRT has the potential 
to be used as an effective therapeutic agent for chronic 
wounds, including poor healing diabetic wounds [14], 
the molecular identity between native and yeast-derived 
CRTs underscores the utility of recombinant CRT 
secreted from yeast as having clinical and commercial 
value for wound healing. As the protein consists of the 
same amino acid sequence, CRT should not be immuno-
genic as a side effect of treatment.
High‑level secretion of recombinant human CRT 
by fed‑batch fermentation of P. pastoris
Development of biopharmaceuticals requires the biosyn-
thesis process to be fully controlled and industrially rel-
evant. P. pastoris is known as a highly efficient expression 
system with well-developed high culture density fermen-
tation protocols. Therefore, we performed synthesis of 
recombinant secreted human CRT using cultivation of P. 
pastoris in a bioreactor and show the results, which can 
be adapted for the production of human CRT protein at 
an industrial scale.
A fed-batch cultivation of P. pastoris clone CPp9 was 
carried out in a 5 l bioreactor Biostat A plus using a four-
step growth protocol, consisting of glycerol batch, glyc-
erol fed-batch, transition phase and methanol fed-batch 
phases. The protocol for the fermentation was adapted 
from Tolner et al. [35] with several modifications to avoid 
proteolytic degradation of secreted human CRT. The 
glycerol batch phase was carried out at 28 °C, instead of 
30  °C, lasted 28  h, and dry cell weight (DCW) reached 
33.5  g/l (Fig.  8). Subsequently, the glycerol batch phase 
pH of the medium was increased to 7 and the glycerol 
fed-batch phase was initiated by adding 50 % glycerol and 
temperature was maintained at 28  °C. Following testing 
the susceptibility of human CRT to proteases released 
into the culture broth by P. pastoris, pH 7 was found to 
Fig. 7 Migration of human dermal fibroblasts induced by native and 
yeast‑derived human CRTs. a Primary human dermal fibroblasts were 
plated, wounded, treated with increasing doses of native placental 
or recombinant human CRTs (0.1–10 ng/ml) and assayed for wound 
closure after 24 h, as described in methods. Experiments were per‑
formed in triplicate. Error bars represent standard deviation (n = 1). 
b Primary human dermal fibroblasts were plated, wounded, treated 
with increasing concentrations of CRT (1–100 ng/ml), and assayed 
for wound closure at 6 h. Experiments were performed in triplicate 
(n = 2). Error bars represent standard error of the mean. A Dunnett’s 
test for statistical significance was performed (*p ≤ 0.05, **p ≤ 0.01, 
and ***p ≤ 0.001)
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ensure optimal stability of the protein (data not shown). 
After 1  h of glycerol-fed batch, DCW reached 42.5  g/l 
(Fig. 8). The transition phase was started by adding 0.2 % 
methanol, ramping down the rate of glycerol feeding to 
0  ml/l/h, and also decreasing the culture broth temper-
ature to 20  °C. This temperature favoured CRT stability 
due to decreased release of proteases by yeast cells. After 
the transition phase, DCW reached 54.4 g/l (Fig. 8) and 
cells adapted to methanol and lower temperature. 20  °C 
temperature was maintained throughout the methanol 
fed-batch phase. Because it was shown [36] that metha-
nol consumption rate at lower temperatures (15  °C) is 
decreased by 25 %, methanol feed rate during induction 
phase was decreased by 50 % to 3.8 ml/l/h compared to 
the feed rate of 7.5 ml/l/h recommended by Tolner et al. 
[35]. Notably, decreasing the methanol feed rate only by 
25 % to 5.6 ml/l/h led to increased proteolytic degrada-
tion of human CRT, thus 3.8  ml/l/h methanol feed rate 
was found to be optimal for biomass and intact protein 
accumulation (Fig.  8). However, after 135  h induction 
(167 h fermentation time), secreted human CRT showed 
signs of degradation and after 183  h induction (215  h 
fermentation time), degradation was severe (Fig.  9). It 
was therefore determined that the optimal induction 
time was 111 h (143 h fermentation time) when secreted 
human CRT concentration reached 1.6 g/l and DCW was 
85.9 g/l (Figs. 8, 9). Specific growth rate on methanol was 
0.0042 h−1. 
Secretion efficiency of human CRT in yeast
To explore the reasons for high-level secretion of human 
CRT, we determined its secretion efficiency by the same 
method as previously reported for human GRP78/BiP 
and ERp57 in yeast [21, 22]. SDS–PAGE analysis of crude 
lysates from S. cerevisiae harbouring pFDC-CRT plasmid 
revealed a more intense band corresponding to the MW 
of recombinant human CRT compared to control cells 
carrying pFDC vector (Fig. 10a, lanes pFDC and pFDC-
CRT). The band of comparable intensity and correspond-
ing to the MW of CRT protein was also observed in crude 
lysate from P. pastoris cells, which expressed CRT by 
high-density fermentation in a bioreactor (Fig. 10a, lane 
PpB-CRT). Quantitative Western blots using antibod-
ies against human CRT protein showed that intracellular 
CRT constituted approximately 1.1 % of total cell protein 
in S. cerevisiae (Fig. 10b, c). Evaluation of protein amount 
according to cell biomass produced from 1 l of S. cerevi-
siae culture revealed that  ~30  % of CRT was expressed 
internally (~25 mg) and ~70 % was secreted into the cul-
ture medium (~60–65 mg). Although there was a higher 
amount of intracellular CRT in P. pastoris constituting 
approximately 2 % of total cell protein (~1.9 and ~2.1 % 
determined in two different experiments shown in 
Fig.  10b, c, respectively), the efficiency of CRT secre-
tion reached ~80 % due to the higher amount of secreted 
protein in the same culture volume (~1.6  g of secreted 
and ~400 mg of internally expressed CRT). Secretion effi-
ciencies of different human ER chaperones in S. cerevi-
siae can be directly compared, because we used the same 
expression procedure for CRT, GRP78/BiP and ERp57. 
Efficiency of CRT secretion (~70  %) was considerably 
higher than either that of GRP78/BiP (~30  %) [21] or 
ERp57 (~20 %) [22]. It suggests that CRT is less efficiently 
retained inside the yeast cells compared to the other two 
Fig. 8 Time‑course profile of CRT secretion in high‑density P. pastoris 
culture during fed‑batch fermentation. Squares represent dry cell 
weight (DCW), diamonds show concentration of the secreted CRT in 
the culture medium. 0–28 h indicate glycerol batch phase, 28–29 h—
glycerol fed‑batch phase, 29–32 h—transition phase, and 32–215 h—
methanol fed‑batch phase. Only the amount of intact secreted CRT 
protein form was calculated
Fig. 9 SDS‑PAGE analysis of culture supernatant from P. pastoris 
fermentation during the methanol fed‑batch stage. Recombinant 
human CRT was produced as shown in Fig. 8 and described in the 
text. 2.5 µl of P. pastoris culture media, taken at different time points, 
was loaded onto each lane. M prestained protein ladder (ThermoSci‑
entific, cat. no. 26616)
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human ER chaperones. Overall higher expression level of 
CRT could only partially contribute to observed higher 
CRT levels in S. cerevisiae culture media. Total CRT 
amount was 85–90 mg/l compared to 50–60 mg/l of the 
other two human ER chaperones (i.e. 1.5–1.8 fold higher, 
when secreted protein amounts differ four- to fivefold), 
but there were even lower CRT amounts inside the cells 
(~25 mg/l vs. 35–50 mg/l for BiP and ERp57). Thus, less 
efficient intracellular retention of CRT is evident from 
this data and it seems to be related to intrinsic properties 
of the protein. It should be noted that all three recombi-
nant human ER chaperones contained an ER-retention/
retrieval signal (KDEL for CRT and BiP, or QDEL for 
ERp57), which did not prevent secretion in yeast. Replac-
ing ER retention signal to yeast preferable ER retention 
signal HDEL did not suppress the secretion of these 
three proteins (our unpublished data). Moreover, over-
load of the yeast ER retrieval machinery as the reason 
for secretion of human ER chaperones can also be omit-
ted, because overexpression of yeast Kar2 protein with 
native HDEL ER retrieval sequence using the same pFDC 
vector did not lead to the secretion of this protein [21]. 
These results indicate that the mechanism(s) involved are 
currently elusive and deserve further investigation. We 
propose that one of the reasons might be limited acces-
sibility of the ER retrieval signals of human ER chaper-
ones in the yeast cells. For example, ER calcium depletion 
was shown to induce CRT secretion [18], whereas free 
Ca2+ in the lumen of the yeast ER is 10–100 times lower 
than that of mammalian ER [37, 38]. Such distinctly dif-
ferent characteristics may result in a CRT conformation, 
which limits accessibility of the KDEL retrieval signal and 
favours protein secretion outside of the yeast cells. Nev-
ertheless, this issue requires additional studies.
Significance and applicability of the results
With a growing demand for human CRT biotherapeutics, 
we introduce yeast S. cerevisiae and P. pastoris as excel-
lent hosts for easily purified, high-level production of 
human CRT. Here we demonstrated that the native signal 
sequence of human CRT precursor is correctly cleaved 
and directs secretion in yeast cells. High-level secretion 
of human CRT using fed-batch fermentation of high-
density P. pastoris culture in a bioreactor allowed effi-
cient production of secreted CRT protein in grams per 
liter scale. To the best of our knowledge, this is one of 
the highest secretion levels achieved using native human 
protein signal sequences in yeast. Comparable results 
after optimization were achieved only with human serum 
albumin (HSA) [39]. Our data suggest that molecular 
integrity and functional activity of yeast-secreted recom-
binant CRT is identical to native CRT protein from 
human placenta. From these results, we can extrapolate 
that CRT secreted by yeast should be inherently biologi-
cally active in any functional in vitro and in vivo acitiv-
ity (harboured by native CRT) with applicability to the 
development of new biopharmaceuticals such as has 
been shown for normal and diabetic wound healing [13, 
14]. Moreover, it was recently shown that this same yeast-
secreted CRT can also be used as a cancer treatment 
adjuvant in combination with photodynamic therapy 
[40]. Yeast-secreted recombinant protein may be advan-
tageous in such applications, because it corresponds to 
the native analogue insofar as possible. Furthermore, 
yeast-derived heterologous proteins are free of toxic con-
taminations and are excellent tools for developing biop-
harmaceuticals, because S. cerevisiae is acknowledged as 
a GRAS (generally regarded as safe) organism. Therefore, 
secretory expression of native recombinant human CRT 
in yeast could be exploited for efficient and safe produc-
tion of potential therapeutic agents.
Conclusions
Our results show that yeast is an excellent host for effi-
cient and industrial scale production of native recombi-
nant human CRT. Yeast cells are able to recognize and 
correctly process the native signal sequence of human 
Fig. 10 Evaluation of amounts of intracellular human CRT protein in 
yeast cells. a SDS–PAGE of crude yeast lysates and indicated amounts 
of purified CRT; b, c two Western blot experiments using monoclonal 
antibodies against human CRT. M prestained protein ladder (Ther‑
moScientific, cat. no. 26616). pFDC, pFDC‑CRT and PpB‑CRT—crude 
yeast lysates (10 μg of whole cell protein in each lane). pFDC and 
pFDC‑CRT indicate samples from S. cerevisiae cells transformed with 
pFDC vector and pFDC‑CRT plasmid, respectively. PpB‑CRT sample 
was taken from fed‑batch fermentation of high‑density P. pastoris cul‑
ture at 111 h induction time in methanol fed‑batch stage (143 h fer‑
mentation time). 50, 75, 100, 150, 200, 300—amounts in nanograms 
of purified S. cerevisiae‑secreted human CRT protein loaded on gel
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CRT precursor. Yeast secretes mature CRT protein into 
the culture medium, instead of retaining the protein in 
the ER. Unusual high-level secretion enabled CRT pro-
duction in grams per liter scale with a simple and cost-
effective purification scheme. Recombinant CRT secreted 
by yeast appears seemingly identical to the native protein 
from human placenta with respect to its molecular integ-
rity and functional activity in vitro. The yeast expression 
and purification systems for human CRT offer a new way 
of producing large quantities of human protein for thera-
peutic application.
Methods
Plasmids, yeast strains, transformation and selection 
of transformants
DNA manipulations were performed according to 
standard procedures [41], bacterial recombinants were 
screened in Escherichia coli DH5αF′ cells. A cDNA 
encoding full-length human calreticulin precursor (Gen-
Bank Acc. no. M84739) was amplified from a commer-
cial human adult liver cDNA library (Clontech) by PCR 
using specific oligonucleotide primers CRTF (gta tct 
aga aca atg ctg cta tcc gtg ccg ttg) and CRTR (cag tct 
aga cta cag ctc gtc ctt ggc ctg), digested with restriction 
endonuclease (RE) XbaI (recognition sites in sequences 
of primers are indicated in bold) and cloned into yeast 
expression vectors pFDC [20] and pPIC3.5K (Invitrogen) 
into RE sites XbaI and AvrII under the control of S. cere-
visiae PGK1 or P. pastoris AOX1 promoters, respectively. 
Cloned CRT gene coding sequence (beginning from start 
codon ATG and ending with STOP codon TAG) was ver-
ified by DNA sequencing and generated plasmids pFDC-
CRT and pPIC3.5K-CRT were used for transformation 
of yeast S. cerevisiae strain AH22 (MATa leu2 his4) and 
P. pastoris strain GS115 (his4), respectively. S. cerevisiae 
transformants were selected by resistance to formalde-
hyde [21] and harboured multicopy autonomously repli-
cating plasmid pFDC-CRT, whereas multicopy P. pastoris 
transformants were selected by resistance to G418 [42] 
and Mut+ clone CPp9 with the most efficient secretion 
of CRT protein was chosen for further experiments. Both 
yeasts were used for expression of the full length CRT 
protein precursor including the native N-terminal signal 
peptide.
Protein expression in shake‑flask cultivations 
and purification of recombinant CRT from yeast culture 
media
Saccharomyces cerevisiae cells harbouring plasmid 
pFDC-CRT were grown for 36 h in YEPD (yeast extract 
1  %, peptone 2  %, dextrose 2  %) medium. P. pastoris 
transformants with multicopy integrations of expres-
sion vector pPIC3.5K-CRT were initially grown in Ygly 
medium containing glycerol as carbon source (yeast 
extract 1 %, peptone 2 %, glycerol 1 %, biotin 2 × 10−5 %) 
for 24  h up to OD of 18–20, and culture medium was 
changed to Ymet containing methanol (yeast extract 1 %, 
peptone 2 %, methanol 1 %, biotin 2 × 10−5 %) for induc-
tion of CRT cDNA expression. Then flasks were further 
incubated in the shaker at 30 °C, 220 rpm for 120 h. 1 % 
of methanol was added every 8  h to maintain protein 
expression. Both P. pastoris and S. cerevisiae cultures 
were centrifuged at 10,000×g for 10 min at 4 °C. Super-
natants were collected and stored on ice. Protocol for 
CRT purification from culture media was the same for 
both yeasts.
Yeast culture medium was microfiltered through 
1.6  µM (Sartorius Stedim Biotech, cat. no. FT-3-1101-
047), 0.45 µM (Sartorius Stedim Biotech, cat. no. 15406-
47) and 0.2  µM (Sartorius Stedim Biotech, cat. no. 
15407-47-MIN) filters using a Pressure Filter Holder 
(Sartorius Stedim Biotech, cat. no. 16249) and a vacuum 
pump. After microfiltration, proteins from the cul-
ture medium were concentrated and transferred into 
the binding buffer (20  mM  l-histidine, 100  mM NaCl, 
pH 5.5) through tangential ultrafiltration using cas-
settes with 100  kDa cut-off membranes (Sartorius Ste-
dim Biotech, cat. no. VF20P4) and a peristaltic pump. 
Further, proteins were loaded onto the column packed 
with Q Sepharose FastFlow resin (GE Healthcare, cat. 
no. 17-0510-10) equilibrated in the same buffer. The 
column was washed with 5 volumes of binding buffer 
and bound proteins were eluted with a NaCl concen-
tration gradient (100–500  mM). CRT was eluted in a 
single peak with approximately 250  mM NaCl. Elution 
fractions containing purified recombinant protein were 
pooled and buffer was exchanged to CRT storage buffer 
(20 mM Tris–HCl, 150 mM NaCl, 3 mM CaCl2, pH 7.5) 
using Sephadex G25 column. Protein was stored frozen 
at −70 °C.
Purification of native CRT from human placenta
Human placentas were donated for research with writ-
ten consent from women who had given birth to healthy 
children at Rigshospitalet, Copenhagen. At the Statens 
Serum Institut they were used anonymously for puri-
fication of CRT. Human placental CRT was purified as 
described previously [26]. Briefly, a placenta was homog-
enized twice in 20 mM BisTris, 1 mM CaCl2, pH 7.5 with 
protease inhibitors (Complete) and with intermittent 
centrifugations. The residue was then extracted twice in 
20 mM BisTris, 1 mM CaCl2, pH 7.5, 1 % Triton X-114 
to release ER luminal proteins. Membrane proteins were 
removed by phase separation at 37 °C and large proteins 
removed from the water phase by ammonium sulphate 
precipitation (337 g/l) overnight at 5 °C. The supernatant 
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was ultradiafiltrated against 20  mM Tris, 1  mM CaCl2, 
pH 7.5 and chromatographed on a Q Sepharose column 
equilibrated in the same buffer and eluted with a linear 
NaCl gradient. CRT-containing fractions were pooled 
and concentrated to 1  mg/ml in 20  mM Tris/HCl, pH 
7.5 using a Centriprep filter. Purified placental CRT was 
stored frozen at −20 °C.
Partial proteolysis of CRT with trypsin in the presence 
of calcium
Partial digestion of CRT with trypsin was performed 
according to previously described procedures [26, 31]. 
Purified yeast-secreted CRT was diluted to 1 mg/ml con-
centration in storage buffer containing 3 mM CaCl2. To 
avoid influence of different storage buffers, native pla-
cental CRT was also transferred to storage buffer with 
3 mM CaCl2 as for recombinant CRTs, and diluted to the 
same concentration. Digestion was performed at 37 °C in 
50 µl volume by adding 1 μl of 0.5 mg/ml trypsin [ratio of 
CRT:trypsin was 100:1 (w/w)]. In a control tube, calcium 
was removed by adding EGTA to 5  mM concentration. 
The reaction was stopped after 60 min, by adding 1 mM 
PMSF. The samples were boiled, loaded onto the gels, and 
SDS-PAGE was performed.
Function of yeast‑derived calreticulin: cellular migration 
and proliferation assays
Cell proliferation An in  vitro assay for cellular prolif-
eration was performed as previously described [13, 14]. 
Primary low passage human dermal foreskin fibroblasts 
(CCD 1070SK; American Type Culture Collection, 
Manassas, VA, USA), grown in complete Eagle’s mini-
mal essential medium (MEM; Gibco/Life Technologies, 
Carlsbad, CA, USA) containing 10 % fetal bovine serum 
(FBS), 2  mM glutamine (Mediatech, Manassas, VA, 
USA), 1.0 mM sodium pyruvate (Gibco) and antibiotics, 
were seeded at 2 ×  103 cells per well in 96 well plates 
and grown to 50 % confluency (24 h). Subsequently, the 
cells were synchronized in media containing 0.5 % FBS 
for 24  h and treated with increasing concentrations of 
CRT (0–100  ng/ml) from placenta, or S. cerevisiae or 
P. pastoris for 72  h. CRT protein concentrations were 
determined by microBCA assay to standardize that 
equal amounts of each CRT were used. The assay was 
performed in triplicate for each test parameter. Media 
with 0.5 % FBS and 10 % FBS served as a negative and 
positive controls, respectively. Proliferation was deter-
mined by an MTS assay (CellTiter96 assay, G3580, 
Promega, Madison, WI, USA). Cells were incubated in 
MTS solution for 1 h and absorbance was measured at 
490 nm (BioRad ELISA reader). The data are expressed 
as fold proliferation over untreated control (n  =  6 
experiments).
Cell migration The effect of native human placen-
tal and yeast-derived human CRT on cellular migra-
tion was assessed by the classic in vitro wound healing 
scratch plate assay, as described [13, 14]. Human der-
mal fibroblasts in complete MEM containing 10 % FBS 
were seeded at 2 ×  104 cells per well in 24 well plates 
and grown to 70–80  % confluency. The cells were 
switched to media containing 0.5  % FBS for 24  h, and 
then wounds were created down the center of each well 
by scratching with a 200  µl pipette tip, and the loose 
cells removed by washing with PBS. The edges of the 
wounds were denoted with a fine-tipped marker on 
the underside of the plate. The cells were treated for 
6 or 24  h with increasing concentrations of CRT pro-
tein in 0.5  % FBS media. 0.5 and 10  % FBS served as 
negative and positive controls, respectively. Migration 
was terminated by incubating the cells with 0.025  % 
Coomassie blue in 10 % acetic acid, 45 % methanol for 
10 min followed by washing twice with PBS. The plates 
were viewed under an inverted light microscope (Axio-
vert s-100; Zeiss, Thornwood, NY, USA) and images 
captured and cell migration calculated by measuring 
the area (pixels) not occupied by cells (i.e., open area 
remaining) to the area of the original scratch at time 
0 using Metamorph software version 7.1.3.0 (Molecu-
lar Probes, Eugene OR, USA). The plates were nor-
malized for cell density at a part of the plate distal to 
the scratch. The data are expressed as per cent wound 
closure (0 time compared to 6 or 24  h later) and the 
averages for each test parameter subjected to analysis 
of variance (ANOVA). Statistical significance for both 
proliferation and wound closure assays were performed 
using GraphPad Prism software (version 6). A two-
way ANOVA followed by a Dunnett post hoc test by 
comparing each treatment value with 0.5 % FBS as the 
untreated control; statistical significance was (p < 0.05). 
The experiments were performed in triplicate (n  =  2 
experiments at 6 h and n = 1 at 24 h).
High cell density fed‑batch fermentation of recombinant P. 
pastoris
For this study, selected Mut+ phenotype P. pastoris 
GS115 transformant strain CPp9 carrying multiple copies 
of human CRT gene under the control of AOX1 promoter, 
was used. A 200 ml culture for inoculation of bioreactor 
was prepared in two stages as described previously [35]. 
First, a 20-ml primary seed YEPD medium was prepared 
using 200 μl of the user seed lot which was grown at 
28  °C in an orbital shaker (New Brunswick Innova 40R) 
at 220 rpm for 24 h. This primary seed medium was used 
to inoculate a 200 ml secondary seed medium, contain-
ing fermentation media, to 0.1 OD that was grown for 
16–18 h to 4–6 OD under the same conditions, to serve 
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as inoculum for the bioreactor culture. Cultures were 
grown in baffled flasks whose volumes were 5× the cul-
ture volume to permit adequate aeration.
High-cell density fed-batch cultivation was performed 
as described previously [35] with several exceptions. Cul-
tivation was carried out in a 5  l BIOSTAT-A plus (Sar-
torius Stedim Biotech) bioreactor interfaced with MFCS/
DA software for data acquisition and control. A 200  ml 
inoculum, prepared as described above, was transferred 
to the bioreactor containing 1.8  l fermentation media. 
The fermentation media contained per liter: glycerol, 
63  g; potassium sulfate, 14.67  g; calcium sulfate, 0.9  g; 
magnesium sulfate hepta-hydrate, 11.67  g; trace metal 
solution (PTM1), 4 ml; ammonium sulfate, 9 g; hexamet-
aphosphate, 25 g. The PTM1 solution contained per liter: 
sodium iodide, 0.08 g; manganese sulfate mono-hydrate, 
3.0  g; sodium molybdate di-hydrate, 0.2  g; boric acid, 
0.02 g; zinc chloride, 20.0 g; ferric sulfate hepta-hydrate, 
65.0  g; cupric sulfate penta-hydrate, 6.0  g; biotin, 0.2  g; 
and sulfuric acid, 5.0  ml. 0.2  ml of antifoam (Antifoam 
204, SigmaAldrich) per 1  l media was added manually 
before inoculation to control foaming in the bioreac-
tor. Aeration rate of 1 vvm was constant throughout the 
whole process. The dissolved oxygen (DO) throughout 
the whole process was controlled at 30 % saturation using 
an automatic DO control by agitation cascade between 
410 and 750 rpm and oxygen supplementation. When a 
maximum 750  rpm was reached, pure oxygen was sup-
plied through a gas blender to control dissolved oxygen at 
30 % saturation.
Temperature during glycerol batch phase was main-
tained at 28  °C and pH at 5.0 with 28  % (v/v) NH4OH. 
After consumption of glycerol, indicated by an increase 
of the DO concentration, glycerol-fed batch phase was 
initiated. Temperature during glycerol-fed batch phase 
was maintained at 28  °C and pH at 7.0. 50  % glycerol 
(v/v) with PTM1 was fed at 20  ml/l/h for 1  h before 
being ramped down to 0  ml/l/h at a uniform rate over 
a 3-h period. The ramping down of glycerol marked the 
beginning of the transition phase and 2 ml/l of methanol 
was added to the bioreactor to allow the cells to adjust 
to methanol. Temperature during transition phase was 
ramped down to 20  °C and pH was maintained at 7.0. 
After transition phase methanol-fed batch phase (pro-
duction of recombinant CRT) was initiated by the addi-
tion of methanol at a 2 ml/l/h rate which was increased 
to 3.8  ml/l/h at a uniform rate over a 6  h period and 
3.8  ml/l/h methanol feed rate was maintained during 
whole methanol-fed batch. Temperature during metha-
nol-fed batch phase was maintained at 20  °C and pH at 
7.0. For DCW determination, cell pellets were washed 
once with distilled water and incubated in an open tube 
to a constant weight at 80 °C.
Miscellaneous
Tryptic peptide mass fingerprinting was carried out at 
the Proteomics Center in the Institute of Biochemistry 
of Vilnius University (Lithuania). S. cerevisiae-secreted 
CRT was analyzed by MALDI-TOF/TOF tandem MS/
MS (mass spectrometry) as described previously [43]. 
Trypsin digestion of P. pastoris-secreted CRT was done 
according to a modified FASP protocol as described by 
Wisniewski et al. [44]. The nano-LC was coupled online 
with an HDMS Synapt G2 mass spectrometer (Waters 
Corporation, UK). LC–MS data were collected using data 
independent acquisition (DIA) mode MSE in combina-
tion with online ion mobility separation.
N-terminal sequencing of yeast-secreted human 
CRT protein by Edman degradation was performed by 
AltaBioscience.
The molecular masses of proteins were measured by 
ESI–MS using an Agilent Q-TOF 6520 mass spectrometer.
Native PAGE was performed exactly as described pre-
viously [21], whereas blue native PAGE was carried out 
according to Niepmann and Zheng [45].
Protein concentrations were determined by Roti-Nano-
quant Protein-assay (Carl Roth Gmbh., cat. no. K880) 
using BSA for calibration curve.
Densitometric analysis of SDS-PAGE gels scanned with 
ImageScanner III (GE Healthcare) was performed with 
ImageQuant TL (GE Healthcare) software using default 
settings. For quantitative analysis of secreted CRT, the 
culture medium was separated from cells by centrifu-
gation, directly mixed with equal amount of 2× SDS-
PAGE sample buffer [46], boiled and loaded onto gel 
lanes. Amounts of secreted CRT in culture medium were 
determined by comparison to a range of known amounts 
of BSA (Fermentas product #B14 was used) in a linear 
dynamic range (R2 > 0.99) of Coomassie-stained protein 
bands in SDS-PAA gels. To determine CRT purity in 
crude yeast culture media, total secreted yeast proteins 
were concentrated by precipitation and yeast protein 
impurities were evaluated by SDS-PAGE.
Precipitation of proteins from yeast culture medium for 
SDS-PAGE analysis was performed based on a defined 
methanol-chloroform-water mixture, as described earlier 
[47].
Mouse monoclonal anti-CRT antibody [FMC 75] was 
purchased from Abcam (cat. no. ab22683-100).
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Additional files
Additional file 1. Different secretion levels of human ER chaperones in 
yeast. SDS‑PAGE (A) and Western blot (B) analysis of 40× concentrated cul‑
ture media of yeast S. cerevisiae AH22 cells transformed with empty plas‑
mid pFDC (lane 1) or producing human chaperones BiP, CRT and ERp57 
(lanes 2, 3 and 4, respectively). Anti‑GRP78 BiP antibody (ab21685), mAb 
anti‑CRT FMC 75 and ERp57 (MaP.ERp57) antibody (sc‑23886) were used in 
Western blots to detect recombinant BiP, CRT and ERp57, respectively.
Additional file 2. Elution profiles of recombinant CRT in anion‑exchange 
chromatography. Separation of CRT from S. cerevisiae (A and B) was 
performed on a pre‑packed 5 ml Q‑Sepharose column (GE LifeSciences 
cat. no. 17‑5156‑01), equilibrated with 20 mM l‑His, pH 5.5, 100 mM NaCl 
buffer, in 15 column volumes linear gradient from 100 mM to 500 mM 
NaCl. Separation of CRT from P. pastoris (C and D) was performed on a 15 
ml Q‑Sepharose sorbent (GE LifeSciences cat. no. 17‑0510‑10) packed into 
the XK 16/20 column (GE Lifesciences, cat. no. 28‑9889‑37), equilibrated 
with 20 mM l‑His, pH 5.5, 100 mM NaCl buffer, in 10 column volumes 
linear gradient from 100 to 500 mM NaCl. Elution profiles (A and C) and 
SDS‑PAGE gels of corresponding fractions (B and D) are shown. Dashed 
lines define fractions that were pooled and used for further experiments 
with purified protein.
Additional file 3. Western blotting analysis of recombinant and native 
human CRTs. The same samples were analysed by SDS‑PAGE (A) and 
Western blot (B) using monoclonal antibodies against human CRT. M—
prestained protein ladders. pFDC and pFDC‑CRT—10× concentrated 
culture media samples from S. cerevisiae transformed with pFDC vector 
and pFDC‑CRT plasmid, respectively. Sc, Pp and Hn—purified CRT from 
S. cerevisiae, P. pastoris and human placenta, respectively. Crude lysate 
of S. cerevisiae cells transformed with pFDC vector was used as negative 
control for Western blot. Bl—blank lanes.
Additional file 4. Comparison of different CRT preparations from S. 
cerevisiae. Four different preparations (A, B, C, D) of purified human CRT 
from S. cerevisiae were analysed by SDS‑PAGE (at the left) and Western 
blotting (at the right) using monoclonal antibodies against human CRT. 
M—prestained protein ladder (ThermoScientific, cat. no. 26616).
Additional file 5. Native PAGE of human placental and recombinant 
CRTs from the same storage buffer. Human placental CRT was transferred 
to the same buffer used for storage of recombinant CRTs (20 mM Tris–HCl, 
150 mM NaCl, 3 mM CaCl2, pH 7.5) and all three CRTs were analysed by 
electrophoresis under native conditions. Blue native PAGE is shown above 
and native PAGE below, all references are the same as in Fig. 2 legend.
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